Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

1501-1520 of 3,900 trials

B-Cell Cancer: INT2104 Infusions

We are investigating the safety of INT2104 infusions for adults with B-cell cancers that have returned after previous treatments. This study aims to understand how well this new treatment works in this patient group.

Refractory B-Cell Malignancies>2 yearsSafety phase (I)Oncology

Gastrointestinal Cancer: Aerosolized Nanoliposomal Irinotecan

We are testing a new aerosolized treatment for patients with peritoneal carcinomatosis from gastrointestinal cancer. This study aims to evaluate the safety and dosage of this innovative approach.

Advanced Peritoneal Metastases from GI CancerSafety phase (I)GastroenterologyOncology

Pulmonary Arterial Hypertension: Sotatercept Study

We are evaluating the long-term safety of sotatercept for adults with pulmonary arterial hypertension already on treatment. This study will help us understand how well it works when added to existing therapies.

Pulmonary Arterial Hypertension>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteCardiology

Advanced Solid Tumors: TransCon IL-2 β/γ Treatment Study

We are investigating the safety and tolerability of TransCon IL-2 β/γ alone and with other cancer therapies for adults with advanced solid tumors. This study aims to find the best dose and understand how it works in combination with existing treatments.

Advanced Solid Tumor Cancers>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Systemic Lupus Erythematosus: Belimumab Study

We are studying the effects of belimumab in adults with early systemic lupus erythematosus to see if it helps improve their condition and reduce steroid use.

Systemic Lupus Erythematosus>2 yearsMonitoring phase (IV)16-20 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteRheumatology

Fecal Microbiome Transplantation for Decompensated Cirrhosis

We are studying whether fecal microbiome transplantation can help slow the progression of decompensated cirrhosis in patients. The trial will assess its effects on survival, complications, and overall health.

Decompensated Cirrhosis1-2 yearsConfirmation phase (III)≤5 visits Investigational MedicinesGastroenterologyHepatology

Targeted Anti-Cancer Drugs: DRUP Trial

We are studying how well existing targeted drugs work for patients with advanced cancers that have specific genetic markers. This trial aims to improve access to effective treatments and gather important data on their use.

Non-Hodgkin LymphomaAdvanced Solid TumorT-cell Prolymphocytic Leukemia3-6 monthsEfficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Kidney Function: Non-Radioactive Measurement Methods

We are evaluating a new non-radioactive method for measuring kidney function in comparison to traditional radioactive techniques. This study aims to ensure accurate assessments while minimizing radiation exposure.

Chronic Kidney Disease3-6 monthsMonitoring phase (IV)No Placebo Standard Medicines Cost ReimbursementInternal MedicineNephrology

Parkinson's Disease: New Treatment Study

We are testing a new treatment in healthy volunteers and individuals with Parkinson's disease, including those with specific genetic mutations. This study aims to understand how the treatment works in different groups.

Parkinson's Disease1-2 yearsSafety phase (I)Neurology

Extrahepatic Cholangiocarcinoma: Durvalumab with Radiofrequency Ablation

We are studying a new treatment combining durvalumab and radiofrequency ablation for patients with bile duct cancer. The goal is to see if this combination improves effectiveness and safety compared to standard therapies.

Extrahepatic Cholangiocarcinoma>2 yearsEfficacy phase (II)>20 visits No Placebo Standard MedicinesGastroenterologyOncology

Sickle Cell Disease: Etavopivat Treatment Study

We are evaluating how well etavopivat works for adolescents and adults with sickle cell disease. The study aims to see if it improves symptoms and quality of life compared to a placebo.

Sickle Cell Disease>2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteHematologyInternal Medicine

Avian Influenza Vaccine: Immune Response Study

We are studying how well a new avian influenza vaccine triggers immune responses in people, especially those with prior seasonal flu vaccinations. This research aims to understand its effectiveness against various H5N1 virus strains.

Avian Influenza and Seasonal Influenza1-2 yearsMonitoring phase (IV)≤5 visits No Placebo Standard MedicinesInfectious DiseasesPulmonology

Mevrometostat for Relapsed/Refractory Cancers

We are testing Mevrometostat in patients with relapsed or refractory small cell lung cancer, castration-resistant prostate cancer, and follicular lymphoma. The goal is to see how well it works in these challenging cases.

Castration Resistant Prostate CancerSmall Cell Lung CancerFollicular Lymphoma>2 yearsSafety phase (I)HematologyOncology

Hand Osteoarthritis: Metformin Treatment

We are investigating whether metformin can reduce finger joint pain in people with hand osteoarthritis. This study compares its effects to a placebo over 16 weeks.

Hand Osteoarthritis3-6 monthsConfirmation phase (III)6-10 visits Standard Medicines Partially RemoteInternal MedicineRheumatology

Heart Attack Treatment: RTP-026 Study

We are exploring a new medication, RTP-026, for patients who have had a heart attack. The study will assess its safety and effectiveness compared to a placebo.

Heart Attack (Acute Myocardial Infarction)1-2 yearsEfficacy phase (II)6-10 visits Investigational Medicines Cost Reimbursement Partially RemoteCardiologyInternal Medicine

Colorectal Cancer Diagnosis: FAPI Imaging Study

We are exploring whether a new imaging method can help diagnose the CSM4 subtype of colorectal cancer more accurately. This study aims to improve detection and treatment options for patients.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)GastroenterologyOncology

Kidney Function: Vonafexor Study

We are studying the effects of vonafexor on kidney function in people with impaired renal function and suspected MASH. The trial will help us understand how different doses impact kidney health and safety.

Impaired Renal Function and Suspected MASH6-12 monthsEfficacy phase (II)≤5 visits No Placebo Standard MedicinesEndocrinologyNephrology

Thyroid Eye Disease: Efgartigimod PH20 SC

We are studying a new treatment for adults with thyroid eye disease to see if it reduces eye bulging compared to a placebo. This trial will help us understand its effectiveness and safety.

Thyroid Eye Disease>2 yearsConfirmation phase (III)Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteEndocrinologyOphthalmology

Thyroid Eye Disease: Efgartigimod PH20 SC Study

We are testing a new treatment called efgartigimod PH20 SC in adults with thyroid eye disease. The goal is to see if it works better than a placebo in reducing symptoms.